Venkataramani, Varun http://orcid.org/0000-0002-2927-0886
Schneider, Matthias
Giordano, Frank Anton
Kuner, Thomas
Wick, Wolfgang
Herrlinger, Ulrich http://orcid.org/0000-0002-4011-9327
Winkler, Frank http://orcid.org/0000-0003-4892-6104
Article History
Accepted: 24 March 2022
First Online: 29 April 2022
Competing interests
: F.W. and W.W. are named on patent WO2017020982A1 entitled “Agents for use in the treatment of glioma”. F.W. was a co-founder of DC Europa Ltd (a company trading under the name Divide & Conquer), which is developing new medicines for the treatment of glioma. Divide & Conquer also provides research funding to F.W.’s laboratory under a research collaboration agreement. F.A.G. has received research grants and personal fees from Carl Zeiss Meditec AG, personal fees from Roche Pharma AG and Medac, grants and personal fees from Elekta AB, Bristol-Myers Squibb, MSD Sharp and Dohme GmbH, AstraZeneca and Guerbet SA, stocks, grants and personal fees from Noxxon Pharma AG and non-financial support from Oncare GmbH and Opasca GmbH. U.H. has received speaker honoraria from Medac, Bayer and Novartis and advisory board honoraria from Bayer, Janssen, Noxxon and Karyopharm. All other authors declare no competing interests.